NCT06679426View on ClinicalTrials.gov

Safety and Efficacy of Conestat Alfa for ACE-Induced Angioedema

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
ACE Inhibitor-Induced Angioedema
Interventions
DRUG

Conestat Alfa

See arm/group descriptions

All Listed Sponsors
collaborator

University of Maryland

OTHER

lead

University of Cincinnati

OTHER

NCT06679426 - Safety and Efficacy of Conestat Alfa for ACE-Induced Angioedema | Biotech Hunter | Biotech Hunter